Novavax
NVAX
137 hedge funds and large institutions have $632M invested in Novavax in 2014 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 65 increasing their positions, 35 reducing their positions, and 21 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
86% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 35
15% more capital invested
Capital invested by funds: $550M → $632M (+$82.3M)
3% less funds holding
Funds holding: 141 → 137 (-4)
15% less call options, than puts
Call options by funds: $5.75M | Put options by funds: $6.77M
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$30.9M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$11M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$7.42M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$6.75M |
| 5 |
BNP Paribas Asset Management
Paris,
France
|
+$6.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$14.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.7M |
| 3 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$6.05M |
| 4 |
HM
HealthCor Management
New York
|
-$3.15M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.96M |
NVAX Hedge Fund Activity: Q2 2014 in Review
137 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q2 2014, worth a combined $632M — up 15% from $550M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of NVAX and 17 opened new positions — a net loss of 4 holders — while 35 trimmed existing stakes and 65 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $30.9M. The largest seller was RA Capital Management, cutting an estimated $14.4M.
- 137 institutional investors held Novavax (NVAX) as of Q2 2014, down from 141 in Q1 2014.
- Funds reported $632M of Novavax stock for Q2 2014, up 15% quarter-over-quarter.
- 17 funds opened new Novavax positions in Q2 2014 and 21 closed out, a net change of -4 holders.
- The largest Novavax buyer in Q2 2014 was T. Rowe Price Associates, an estimated $30.9M added.
- The largest Novavax seller in Q2 2014 was RA Capital Management, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2014.